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Summary
The care for a patient with ulcerative colitis (UC) remains
challenging despite the fact that morbidity and mortality
rates have been considerably reduced during the last 30
years. The traditional management with intravenous cor-
ticosteroids was modified by the introduction of ciclospor-
in and infliximab. In this review, we focus on the treatment
of patients with moderate to severe UC. Four typical clin-
ical scenarios are defined and discussed in detail. The treat-
ment recommendations are based on current literature, pub-
lished guidelines and reviews, and were discussed at a
consensus meeting of Swiss experts in the field. Compre-
hensive treatment algorithms were developed, aimed for
daily clinical practice.
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Introduction
Ulcerative colitis (UC) is a chronic relapsing and remitting
inflammatory disorder of the gastrointestinal tract, and, be-
sides Crohn’s disease (CD), it is one of the two major forms
of inflammatory bowel disease (IBD) [1].
The aetiology of UC remains unclear. Medical therapies
to completely cure the disease are not available. Genetic,
immunologic and environmental factors are likely to play
a role in UC pathogenesis. Currently, the most widely ac-
cepted hypothesis implicates a combination of the follow-
ing factors: immune deregulation (caused by genetic or en-
vironmental factors), abnormal gastrointestinal (GI) tract
luminal factors, (such as microorganisms constituting the
GI tract flora, oxidative stress, and tumour necrosis factor
(TNF) -alpha) and defects in the GI mucosal barrier that al-
low luminal factors to penetrate into the mucosa [2–7].
The clinical presentation of UC is characterised by abdom-
inal pain, diarrhoea with or without hematochezia, and mu-
cosal ulcerations [8]. The extent of disease varies from lim-
ited involvement of the rectum to involvement of the whole
colon, and seldom of the terminal ileum (backwash ileitis).
Clinically, mild disease is associated with fewer than 4
bowel movements per day, with or without bloody stools
but without systemic manifestations and blood tests are
usually normal. Moderate disease is associated with more
than 4 bowel movements a day with minimal systemic
manifestations. The simplest clinical measure to distin-
guish moderate from mildly active colitis is the presence
of mucosal friability (bleeding on light contact with the
rectal mucosa at sigmoidoscopy) [9]. Severe disease de-
scribes disease associated with more than 6 bowel move-
ments a day, with blood in the stool and with systemic in-
volvement [10, 11] (table 1).
During relapses or flares, pharmacological or surgical in-
tervention is needed to re-establish symptom free remis-
sion. Ideally, medical strategies are employed to maintain
patients in long-term remission, while minimising steroid
dependence and therapy-related toxicity.
While most acute flares of UC are mild and manageable
on an ambulatory basis, more severe flares requiring hos-
pitalisation appear in about 15% of all cases [12]. Thirty
to forty years ago, mortality in these patients reached up
to 25%. With the introduction of intravenous corticoster-
oids, modern intensive care treatment, earlier recognition
of treatment failure and advanced surgical techniques, mor-
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tality has decreased to less than one percent in specialised
centres [11, 13, 14].
In this review, we focus on the treatment of patients with
moderate to severe UC. Four typical clinical scenarios are
defined and discussed in detail. The recommendations are
based on the current literature and published guidelines and
reviews [15–20] (up to end of 2009). They were finally dis-
cussed at a consensus meeting (22nd June 2010) with the
above mentioned IBD experts. Based on the discussion,
a comprehensive treatment algorithm could be developed
and was agreed upon by the board members. These treat-
ment algorithms are aimed for daily clinical practice at col-
leagues who regularly treat patients with UC.
Active ulcerative colitis of any extent
not responding to 5-ASA (fig. 1)
The first line treatment of mild to moderate left sided UC
or pancolitis is combined topical and oral aminosalicylates
[20]. The combination of oral and rectal mesalamine seems
to be superior to either therapy alone in patients with ex-
tensive colitis [21]. 5-ASA is superior to placebo for in-
duction of remission. In cases of failure to induce global
or clinical improvement or remission, the pooled Peto odds
ratio is 0.40 (95% confidence interval (CI), 0.30 to 0.53)
[22].
Patients with a first flare or patients with a maximum of
one flare per year requiring systemic steroids should be
Figure 1
started on 0.75–1 mg/kg of oral prednisone-equivalent for
two to four weeks [15, 20, 23–25]. After successful taper-
ing of the steroids, maintenance therapy with topic and/
or oral 5-ASA can be re-established [22, 26–28]. If remis-
sion cannot be maintained, the next course of oral ster-
oids should be combined with azathioprine (AZA) or mer-
captopurine (6-MP) at 2–2.5 mg/kg or 1–1.5 mg/kg, re-
spectively [15, 20, 29, 30].
In a patient not responding to oral steroids, infection must
be excluded. Stool cultures for bacteria and parasites and
an assay for clostridium (Cl.) difficile must be obtained
[31]. Sigmoidoscopy should be performed to confirm the
diagnosis and to exclude cytomegalovirus (CMV) infection
[32, 33]. If infection is excluded, treatment failure in this
situation is called steroid-refractory. This topic will be dis-
cussed in the corresponding section below.
If a patient fails to taper corticosteroids within less than 16
weeks or a patient relapses within 12 weeks after corticos-
teroid discontinuation they are considered to be steroid-de-
pendent (see the corresponding section below).
In a patient requiring more than one cycle of systemic ster-
oids per year or in a patient with a poor projected pro-
gnosis (e.g., young age, severe first flare, severe systemic
inflammation, slow response to steroids), oral prednisone-
equivalent should be combined with azathioprine (AZA) or
mercaptopurine (6-MP) at 2–2.5 mg/kg or 1–1.5 mg/kg, re-
spectively [15, 20, 29, 30].
If tapering of the steroids is successful, maintenance-ther-
apy with AZA/6-MP at the mentioned dose should be con-
tinued. In case of failure of this treatment including a trial
with intravenous steroids (and excluding infection), the pa-
tient is considered as steroid-refractory. Further treatment
will be discussed in the corresponding section. If a patient
has had a full dose of AZA/6-MP for more than 12 weeks
and fails to taper corticosteroids within 16 weeks, or re-
lapses within 12 weeks after cessation of steroids, they are
considered as steroid-dependent and an AZA/6-MP fail-
ure and should be treated according to the appropriate al-
gorithm below.
Table 1: Disease Activity in UC, adapted from Truelove and Witts (11)
Patient
characteristics
Mild Moderate Severe
Light clinical symptoms, but which can be
worsened by the subjective perception of the
patient.
Especially urgencies contribute to a more severe
perception of the disease.
Localization of the disease is important as topical
treatments will have to be adjusted accordingly.
Increased clinical symptoms but only mild systemic
symptoms.
Steroid use is a good criterion to classify a patient
as moderate (or severe).
Presence of mucosal friability (bleeding on light
contact with the rectal mucosa on sigmoidoscopy).
Severe active ulcerative colitis is best
defined by Truelove and Witts' Criteria.
Patients should be admitted to hospital
for intensive treatment
Bloody stools per day < 4 ≥ 4 ≥ 6
Pulse < 90 bpm ≤ 90 bpm > 90 bpm
Temperature < 37.5 °C ≤ 37.5 °C > 37.8 °C
Hemoglobin > 11.5 g/dl ≥ 10.5 g/dl < 10.5 g/dl
ESR < 20 mm/h ≤ 30 mm/h > 30 mm/h
CRP Normal ≤ 30 mg/L > 30 mg/L
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Steroid-dependent ulcerative colitis
(fig. 2)
Steroid-dependent ulcerative colitis defines a patient who
fails to taper steroids below 10mg within 16 weeks from a
starting dose of 0.75–1 mg/kg oral prednisone-equivalent,
or who relapses within 12 weeks after steroid discontinu-
ation [31]. In this situation, compliance to 5-ASA must be
checked first. Infection as a cause for therapy-failure must
be ruled out by appropriate stool tests. CMV colitis should
be excluded by sigmoidoscopy with biopsies. Before intro-
ducing azathioprine or mercaptopurine, a full blood count
including absolute lymphocyte numbers must be obtained.
Measurement of the activity of Thiopurin-S-Methyltrans-
ferase (TPMT) can be considered to identify patients at
high risk for severe myelodepression under therapy with
thiopurines [34–36]. Alternatively, regular testing of the
full white blood count (WBC) is mandatory. Azathioprine
is significantly more effective than mesalazine at inducing
clinical and endoscopic remission in the treatment of
steroid-dependent UC [30].
Any patient with steroid-dependent ulcerative colitis or
with an early relapse is best started on azathioprine (AZA)
at 2-2.5 mg/kg. In case of gastrointestinal intolerance or a
flu-like syndrome, after exclusion of pancreatitis or hepato-
pathy, a switch to mercaptopurine (6-MP) at 1–1.5 mg/kg
can be done. AZA/6-MP needs at least 12 weeks to be fully
effective.
AZA/6-MP failure is present, if a patient fails to taper cor-
ticosteroids after 12–24 weeks of full dose therapy or if
the patient relapses within 12 weeks after steroid tapering.
Again, compliance must be secured and infection ruled out.
In this clinical scenario, induction treatment with inflixim-
ab at 5–10 mg/kg can be considered with infusions given
Figure 2
at week 0, 2 and 6 followed by an infusion every 8 weeks
[37]. As an alternative, oral tacrolimus at 0.1–0.2 mg/kg
may be tried [16, 38]. The targeted trough level for induc-
tion therapy is 10–15 ng/ml [39]. A patient who is still
refractory to treatment should be referred to a specialised
centre with profound experience in IBD and adequate in-
frastructure. Surgery must always be considered as an al-
ternative in the refractory patient.
Steroid-refractory ulcerative colitis
(fig. 3)
A patient not responding to 0.75–1 mg/kg of oral
prednisone-equivalent within two to four weeks is defined
as steroid-refractory ulcerative colitis [10, 31]. This dia-
gnosis is made after exclusion of an infection and is best
re-assessed by colonoscopy and biopsy to confirm the dia-
gnosis and/or to rule out complications.
If the patient is in a stable clinical condition without the
need for rapid induction, AZA at 2–2.5 mg/kg or 6-MP at
1–1.5 mg/kg should be added [20]. If there is still no remis-
sion after a full dose within 12–24 weeks, a switch to in-
fliximab at 5–10 mg/kg at week 0, 2 and 6 followed by an
infusion every 8 weeks [17, 37, 40] should be considered.
If the patient is still refractory to this treatment, a third-
line immunosuppressive therapy or surgery must be con-
sidered. This patient should or must be referred to a spe-
cialised centre.
If there is a need for rapid induction of remission in a
severely ill patient and the patient is AZA-naïve, steroids
must be given intravenously. Intravenous (iv) steroids
(such as 60 mg of methylprednisolone or 400 mg of hydro-
cortisone daily) remain the mainstay of conventional ther-
apy [20, 41]. Higher doses are not more effective, but lower
doses are less effective [42, 43]. The expected overall re-
sponse rate of steroids is 67% [43]. In case of response to
treatment, AZA at 2–2.5 mg/kg or 6-MP at 1–1.5 mg/kg
should be added and steroids can be slowly tapered. If there
is no response to iv-steroids after 2 weeks, intravenous cyc-
losporin at a dose of 2 mg/kg should be started [20, 44, 45].
Cholesterol levels should be checked before the start of
cyclosporine. A prophylaxis against pneumocystis jiroveci
may be installed [46, 47] as a combined immunosuppres-
sion entails an increased risk. In case of response to i.v.
cyclosporine, AZA at 2–2.5 mg/kg or 6-MP at 1–1.5 mg/kg
Figure 3
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should be added and oral cyclosporine should be continued
for at least three month as a bridging therapy [16]. In case
of non- response within two weeks, third-line immunosup-
pressive therapy or surgery must be considered at a special-
ised centre.
If a patient was a prior AZA/6-MP failure, infliximab at 5
mg/kg can be started [48–52]. In case of lack of response
after two infusions or no remission after ten weeks, the
dose should be doubled to 10 mg/kg. In a patient still not
responding, third-line immunosuppressive therapy or sur-
gery must be considered at a specialised centre.
Acute (fulminant) ulcerative colitis
(fig. 4)
Acute severe or fulminant ulcerative colitis is best defined
according to the index of Truelove and Witts (table 1) [11].
It defines a patient with a bloody stool frequency of more
than five per day AND tachycardia >90 bpm, OR a temper-
ature >37.8°, OR anaemia with a haemoglobin <10.5 g/dl,
OR an elevated CRP (>30 mg/l) or ESR (>30 mm/h), re-
spectively. A patient fitting these criteria must be admitted
to hospital and needs intensive treatment.
First line treatment is intravenous application of steroids
such as 60 mg of methylprednisolone or 400 mg of hy-
drocortisone daily [20, 41]. If the AZA-naïve patient does
not respond (sustained fever, bloody diarrhoea more than
4 times daily or continued elevated CRP) on day 3–7, iv
ciclosporin or infliximab should be started [20]. Cyclospor-
in is given at a dose of 2 mg/kg [20, 44, 45] after ex-
clusion of hypomagnesaemia. Cyclosporin trough levels
must be checked on day 3, dependent on the assay and
the local laboratory (it should be between 300 and 500 ng/
ml). In case of clinical improvement, AZA at 2–2.5 mg/
kg or 6-MP at 1–1.5 mg/kg should be started before dis-
charge and oral cyclosporin should be continued for at least
three months as a bridging therapy [16]. If no improvement
is achieved within 5–7 days, infliximab may be tried or
colectomy must be performed.
As an alternative to cyclosporine, infliximab may be started
with 5 mg/kg at week 0, 2 and 6 [48–52, 54]. If no clinical
improvement occurs within 7–10 days or a deterioration is
developing, surgery must be considered. In case of clinic-
al improvement, infliximab should be continued at 5 mg/kg
every 8 weeks.
Figure 4
Patients who are already on a therapy with AZA/6-MP at
the time of their severe flare seem to respond poorly to cyc-
losporin [55, 56]. If they fail iv-steroids, infliximab should
be started at 5 mg/kg and continued every 8 weeks if an im-
provement occurs. In case of failure or deterioration, sur-
gery must be considered. Tacrolimus may be an alternative
in specialised centres [20, 39, 57, 58].
Conclusions
The care for a patient with moderate to severe ulcerative
colitis remains challenging despite the fact that morbidity
and mortality rates have been considerably reduced during
the last 30 years. 5-ASA, thiopurines and infliximab are
well established treatment regimens for the maintenance of
remission. 5-ASA are considered the standard in treating
mild to moderate UC. For inducing remission in refractory
patients and in severe disease cases, corticosteroids remain
the first line therapy. With the administration of cyclospor-
in and infliximab as rescue therapies in severe refractory
cases, morbidity and mortality can be clearly reduced.
The early detection and/or the prophylaxis of complica-
tions, better intensive care and the improvement of anaes-
thesiological and surgical techniques have contributed to
better outcomes. One of the most important factors remains
the close teamwork between the gastroenterologist and the
surgeon at all times during the clinical course in order not
to miss the best timing for colectomy, which will still be
necessary in about 30% of the patients with severe ulcerat-
ive colitis.
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